Shares of CeriBell (NASDAQ:CBLL - Get Free Report) have earned a consensus recommendation of "Buy" from the six analysts that are currently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $32.60.
CBLL has been the subject of several recent analyst reports. JPMorgan Chase & Co. began coverage on CeriBell in a research note on Tuesday, November 5th. They set an "overweight" rating and a $32.00 target price for the company. TD Cowen upped their target price on shares of CeriBell from $31.00 to $36.00 and gave the stock a "buy" rating in a research report on Monday, December 9th. Canaccord Genuity Group started coverage on CeriBell in a research note on Tuesday, November 5th. They issued a "buy" rating and a $30.00 price target for the company. William Blair started coverage on shares of CeriBell in a research note on Tuesday, November 5th. They set an "outperform" rating on the stock. Finally, Bank of America assumed coverage on shares of CeriBell in a research note on Tuesday, November 5th. They set a "buy" rating and a $32.00 target price on the stock.
View Our Latest Research Report on CeriBell
CeriBell Price Performance
Shares of CeriBell stock traded down $0.46 during trading hours on Thursday, reaching $21.44. The stock had a trading volume of 302,166 shares, compared to its average volume of 168,812. CeriBell has a 1 year low of $18.69 and a 1 year high of $32.75. The business's 50 day simple moving average is $24.22.
Hedge Funds Weigh In On CeriBell
Hedge funds have recently made changes to their positions in the business. FMR LLC bought a new stake in CeriBell during the fourth quarter worth approximately $128,120,000. Corebridge Financial Inc. bought a new stake in shares of CeriBell during the 4th quarter worth $158,000. Board of Trustees of The Leland Stanford Junior University acquired a new position in shares of CeriBell in the 4th quarter worth $16,143,000. Norges Bank acquired a new stake in shares of CeriBell during the fourth quarter worth $422,000. Finally, Next Century Growth Investors LLC acquired a new position in shares of CeriBell in the 4th quarter valued at $5,299,000.
About CeriBell
(
Get Free ReportWe are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
See Also
Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
